GlassScriptPhysician profile
Amy E Nugent
NPI 1245299288
$11,519.74
in general payments reported to CMS, 2019-2025
31 companies · $1,699 in 2025
The $1,699 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,251 · 2022: $2,601 · 2023: $2,848 · 2024: $2,120 · 2025: $1,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,668.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,123.45 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,231.65 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $624.36 | 2021-2025 | Epclusa |
| Nestle Healthcare Nutrition INC. | $524.93 | 2021-2023 | |
| Janssen Biotech, INC. | $453.14 | 2021-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $435.95 | 2021-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $245.92 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $228.39 | 2023-2025 | Sucraid |
| Enterra Medical, INC. | $213.28 | 2023 | |
| Ardelyx, INC. | $155.64 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $133.52 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $124.99 | 2021 | |
| Vivus LLC | $120.99 | 2023-2025 | Pancreaze |
| Ironwood Pharmaceuticals, INC | $109.03 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $95.11 | 2022-2024 | Dificid, Zerbaxa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $89.00 | 2021-2023 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $82.67 | 2021-2022 | |
| Pfizer INC. | $70.20 | 2021-2024 | |
| Genzyme Corporation | $65.34 | 2022-2025 | |
| Lilly USA, LLC | $57.26 | 2024-2025 | Omvoh |
| Celgene Corporation | $56.31 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $46.76 | 2024-2025 | Vowst |
| Redhill Biopharma INC. | $36.71 | 2022 | |
| Fresenius Kabi USA, LLC | $33.64 | 2024 | Idacio |
| Amgen INC. | $29.90 | 2023 | Avsola |
| Novo Nordisk INC | $28.18 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $25.59 | 2022 | |
| Ferring Pharmaceuticals INC. | $23.03 | 2022 | |
| Medtronic, INC. | $20.20 | 2025 | Interstim |
| Alcresta Therapeutics, INC. | $19.46 | 2024 | Relizorb |
| Daiichi Sankyo INC. | $15.14 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Nugent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.